Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Trends in Endocrinology   Volumes    Volume 8 
Denosumab as a bridge to surgery in patients with primary hyperparathyroidism, severe hypercalcemia and renal impairment
F. Pugliese, D. de Martino, A. Scillitani, V. Carnevale
Pages: 41 - 44
Number of pages: 4
Current Trends in Endocrinology
Volume 8 

Copyright © 2016 Research Trends. All rights reserved

Severe hypercalcemia caused by primary hyperparathyroidism mandates prompt parathyroidectomy but increases intra-operative risk, and consequently serum calcium levels should be lowered before surgery. We report two patients with severe hypercalcemia and moderate renal impairment treated with the monoclonal antibody denosumab as a bridge to surgery, although the drug had never been used so far for this purpose. The antiresorptive drug denosumab interferes with the RANKL/RANK (Receptor Activator of Nuclear Factor κ B-ligand/Receptor Activator of Nuclear Factor κ B) signaling, thus inhibiting bone resorption, allowing the quick attainment of adequate serum calcium levels. Our cases suggest the possible use of denosumab in the pre-surgical management of severe hypercalcemia, resulting from both benign and malignant parathyroid disease. Such a “bridge” therapy could be suitable for allowing a prompt and safer parathyroidectomy even in patients with impaired renal function.
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms